Found: 12
Select item for more details and to access through your institution.
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID).
- Published in:
- Cancer Medicine, 2024, v. 13, n. 7, p. 1, doi. 10.1002/cam4.7107
- By:
- Publication type:
- Article
Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
- Published in:
- Oncologist, 2024, v. 29, n. 3, p. e330, doi. 10.1093/oncolo/oyad296
- By:
- Publication type:
- Article
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 1, p. 132, doi. 10.1007/s10120-022-01349-y
- By:
- Publication type:
- Article
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 5, p. 1011, doi. 10.1007/s10637-022-01285-9
- By:
- Publication type:
- Article
Short bevacizumab infusion as an effective and safe treatment for colorectal cancer.
- Published in:
- Molecular & Clinical Oncology, 2022, v. 17, n. 3, p. N.PAG, doi. 10.3892/mco.2022.2572
- By:
- Publication type:
- Article
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
- Published in:
- Oncology & Therapy, 2022, v. 10, n. 1, p. 253, doi. 10.1007/s40487-022-00188-2
- By:
- Publication type:
- Article
A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2017, v. 13, n. 2, p. e132, doi. 10.1111/ajco.12405
- By:
- Publication type:
- Article
Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
- Published in:
- Oncology Reports, 2014, v. 32, n. 2, p. 829, doi. 10.3892/or.2014.3227
- By:
- Publication type:
- Article
Morphological study of the TK cholangiocarcinoma cell line with three-dimensional cell culture.
- Published in:
- Molecular Medicine Reports, 2014, v. 9, n. 4, p. 1359, doi. 10.3892/mmr.2014.1939
- By:
- Publication type:
- Article
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
- Published in:
- International Journal of Clinical Oncology, 2013, v. 18, n. 6, p. 1020, doi. 10.1007/s10147-012-0478-5
- By:
- Publication type:
- Article
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
- Published in:
- International Journal of Cancer, 2012, v. 130, n. 10, p. 2359, doi. 10.1002/ijc.26282
- By:
- Publication type:
- Article